Adaptive Biotechnologies Future Growth
Future criteria checks 1/6
Adaptive Biotechnologies is forecast to grow earnings and revenue by 24.8% and 18.5% per annum respectively. EPS is expected to grow by 26.1% per annum. Return on equity is forecast to be -88.8% in 3 years.
Key information
24.8%
Earnings growth rate
26.1%
EPS growth rate
| Life Sciences earnings growth | 26.2% |
| Revenue growth rate | 18.5% |
| Future return on equity | -88.8% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 264 | -102 | -29 | -96 | 6 |
| 12/31/2025 | 211 | -140 | -57 | -127 | 8 |
| 12/31/2024 | 178 | -164 | -73 | -122 | 8 |
| 9/30/2024 | 177 | -195 | -115 | -110 | N/A |
| 6/30/2024 | 169 | -213 | -137 | -129 | N/A |
| 3/31/2024 | 175 | -215 | -145 | -136 | N/A |
| 12/31/2023 | 170 | -225 | -167 | -156 | N/A |
| 9/30/2023 | 180 | -196 | -171 | -159 | N/A |
| 6/30/2023 | 190 | -191 | -170 | -155 | N/A |
| 3/31/2023 | 184 | -195 | -195 | -179 | N/A |
| 12/31/2022 | 185 | -200 | -200 | -184 | N/A |
| 9/30/2022 | 168 | -221 | -231 | -208 | N/A |
| 6/30/2022 | 160 | -232 | -241 | -209 | N/A |
| 3/31/2022 | 155 | -229 | -248 | -199 | N/A |
| 12/31/2021 | 154 | -207 | -254 | -193 | N/A |
| 9/30/2021 | 147 | -190 | -241 | -179 | N/A |
| 6/30/2021 | 133 | -171 | -234 | -182 | N/A |
| 3/31/2021 | 116 | -155 | -208 | -176 | N/A |
| 12/31/2020 | 98 | -146 | -168 | -150 | N/A |
| 9/30/2020 | 92 | -122 | -148 | -137 | N/A |
| 6/30/2020 | 92 | -99 | -131 | -120 | N/A |
| 3/31/2020 | 93 | -82 | -115 | -105 | N/A |
| 12/31/2019 | 85 | -70 | 194 | 205 | N/A |
| 9/30/2019 | 78 | -62 | 215 | 227 | N/A |
| 6/30/2019 | 69 | -56 | 235 | 245 | N/A |
| 3/31/2019 | 59 | -53 | 243 | 252 | N/A |
| 12/31/2018 | 56 | -46 | -39 | -32 | N/A |
| 12/31/2017 | 38 | -43 | N/A | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1HM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1HM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1HM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1HM's revenue (18.5% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 1HM's revenue (18.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1HM is forecast to be unprofitable in 3 years.